All News #Library
Biotech
RayzeBio Announces First Patient Dosed in PIII ACTION-1 Study, Evaluating RYZ101
31 May 2023 //
BUSINESSWIRE
RayzeBio Nominates Glypican-3 Targeted Radiopharmaceutical Therapy Drug Candidate
21 Mar 2023 //
BUSINESSWIRE
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101
20 Mar 2023 //
BUSINESSWIRE
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
04 Jan 2023 //
BUSINESSWIRE

Market Place
Sourcing Support